Respond to prefers-color-scheme dark in app web views

Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

Biden is aiming increasingly personal and sarcastic jabs at Trump

Eric Adams’s condescending dismissal of the ‘children’ at Columbia

Election 2024 live updates: Trump holds rallies in Wisconsin, Michigan during court break

How to make the most of Passport DC’s free embassy tours

Where to watch the Kentucky Derby in D.C.

Chance to move over .500 slips away as Nats lose to reigning champs

France shows its anger on May Day ahead of Paris Olympics

One photo, one night in Rafah

Is Bougainville the next battleground between China and the U.S.?

A murder plot that cannot be ignored: India must come clean at last

How to confront antisemitism, deal with protests — and respect free speech

Is student loan debt an emergency? Take our quiz.

Biden’s internet-for-all program needs Musk’s help

The tech billionaires who helped ban TikTok want to write AI rules for Trump

Cat climbed into Amazon return box, found alive 630 miles away

I learned to heal my sadness by cradling dying chickens 

Brave Little Hunter is free: Baby orca escapes lagoon for open seas

Adaptive adventures are making national parks more inclusive

Man arrested at Yellowstone for allegedly kicking bison while drunk

Southwest passengers now get a $75 voucher for big flight disruptions

Carolyn Hax: Too late to accept a decade-old apology, accidentally left unread?

I coach my son’s sports team. Why is he so disrespectful during practice?

Miss Manners: How to decline donation requests at checkout

Riding the rails with hobos and crust punks

In photos: Violence erupts at campuses as activists and counterprotesters clash

Drone video shows trapped baby orca in B.C. lagoon

UnitedHealth grew very big. Now, some lawmakers want to chop it down.

The new face of flooding

How celebrity tequilas are changing the very nature of tequila

Use these 6 points to say no to a college you and your kid can’t afford

How this new rule protects retirement savers from costly advice

Borrowers, don’t miss this important student loan forgiveness deadline

 Donald Trump Speaks During A Campaign Rally In Green Bay Wisconsin

EpiPen maker Mylan announced Monday morning that it would introduce a generic version of the lifesaving allergy injection at half the price of the brand-name product, after politicians blasted the company for a drug coupon program seen as a public relations Band-Aid.

The generic, which the company said will be launched "in several weeks," will carry a list price of $300 for a two-pack carton. That is half the list price for the branded product, which costs $608 for a two-pack, but it is still nearly $40 more than the price three years ago, according to data from Truven Health Analytics.

"We understand the deep frustration and concerns associated with the cost of EpiPen to the patient, and have always shared the public's desire to ensure that this important product be accessible to anyone who needs it," Mylan chief executive Heather Bresch said in a <a href="http://newsroom.mylan.com/2016-08-29-Mylan-to-Launch-First-Generic-to-EpiPen-Auto-Injector-at-a-List-Price-of-300-per-Two-Pack-Carton-a-More-than-50-Discount-to-the-Brand-Product" target="_blank">statement</a>. "Our decision to launch a generic alternative to EpiPen is an extraordinary commercial response."


<i>
    [Why Mylan’s ‘savings card’ won’t make EpiPen cheaper for all patients]
  </i>


Joshua Sharfstein, a professor of health policy and management at the Johns Hopkins Bloomberg School of Public Health, called it a face-saving move by the company. The generic offers a way of dropping the price of one version of the drug, while also bringing the company some benefits. It will allow Mylan to segment the market, because some people will continue to buy the brand-name product.

Sharfstein said one important question will be whether the price stays the same over time.

The introduction of Mylan's generic also won't automatically open the window to true competition from other generic companies, according to Michael Carrier, a professor at Rutgers Law School. Companies can introduce generics of their brand-name drugs, called "authorized generics," but the effect on competition is ambiguous, he said.

"We have more competition than we did yesterday, but on the other hand, we don’t have wide-open competition among the generics," Carrier said. "And maybe by having this authorized generic, we’re keeping at bay some of that true competition."

He noted that when the first generic drug enters the market, it usually gets a very shallow discount off the brand-name list price — maybe 5 or 10 percent. It is only when multiple generics enter that deeper discounts occur. The deep initial discount off the brand-name price could make the market less attractive to generics companies.

"I think that’s what we've seen over the past week, where Mylan realizes it is in political hot water, and so it is doing a whole bunch of things to make it seem like it’s lowering the price — and for some consumers it will help," Carrier said. "These are measures that Mylan is taking to lower the price, but notice it has not lowered the list price of the drug at all."

Sen. Richard Blumenthal raised the same question in a statement.

"Myl‎an may appear to be moving in the right direction, but its announcement raises as many questions as solutions — including why the price is still astronomically high, and whether its action is a preemptive strike against a competing generic," Blumenthal (D-Conn.) said.

Teva Pharmaceutical Industries has been trying to launch a generic version of the drug, but it was rejected by regulators earlier this year for "certain major deficiencies," according to a spokeswoman, and product launch has been delayed until at least 2017.

Public Citizen, a patient advocacy group, noted that not everyone will get access to the generic, making it an incomplete solution to the high price — similar to the critique leveled at the coupons and patient assistance.

"The weirdness of a generic drug company offering a generic version of its own branded but off-patent product is a signal that something is wrong," Public Citizen President Robert Weissman said in a statement. Mylan "aims to continue ripping off some segment of the marketplace — both consumers who do not trust or know about the generic, and perhaps some insurers and payers constrained from buying a generic."

He noted that the price in Canada is $200 for a two-pack of EpiPens and that the price in France was even lower.

<a href="https://www.washingtonpost.com/business/economy/2016/08/25/7f83728a-6aee-11e6-ba32-5a4bf5aad4fa_story.html" target="_blank">How Mylan, the maker of EpiPen, became a virtual monopoly</a>

<a href="https://www.washingtonpost.com/business/economy/high-prices-make-once-neglected-orphan-drugs-a-booming-business/2016/08/04/539d0968-1e10-11e6-9c81-4be1c14fb8c8_story.html">High prices make once-neglected ‘orphan’ drugs a booming business</a>

<a href="https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6_story.html">This drug is defying a rare form of leukemia — and it keeps getting pricier</a>

Finalist for the 2013 Pulitzer Prize in national reporting, as part of a team

Amherst College, BA in Physics and English

MIT, MS in Science Writing

Carolyn Johnson is a science reporter. She previously covered the business of health and the affordability of health care to consumers. 